Clodronate in myelofibrosis: a case report.
A 59-year-old man had well-documented agnogenic myeloid metaplasia (AMM) with pancytopenia. Frequent blood transfusions were required over a 10-month period. Androgen therapy was not beneficial and treatment with interferon resulted in severe thrombocytopenia with no decrease in transfusion requirements. Treatment with clodronate at a daily oral dose of 30 mg/kg resulted in a marked decrease in bone marrow fibrosis, and gradual normalization of blood counts over an 8-month period. He has been transfusion independent for the last 33 months. We support the findings of a previous case report that oral bisphosphonate therapy may be of value in patients with AMM.
Froom
Paul
P
Institute of Hematology, Lady Davis Carmel Hospital, Haifa, Israel.
Elmalah
Irit
I
Braester
Andrei
A
Aghai
Ester
E
Quitt
Miriam
M
D000963:Antimetabolites / Q000627:therapeutic use; D001803:Blood Transfusion; D001854:Bone Marrow Cells / Q000166:cytology / Q000378:metabolism; D004002:Clodronic Acid / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D055728:Primary Myelofibrosis / Q000188:drug therapy* / Q000503:physiopathology
D000963:Antimetabolites; D004002:Clodronic Acid